The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HURA | -82.63% | -99.92% | -75.81% | -84% |
| S&P | +14.11% | +87.98% | +13.46% | +17% |
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 27.6% |
| Market Cap | $124.12M | 1566.9% |
| Market Cap / Employee | $6.53M | 0.0% |
| Employees | 19 | 0.0% |
| Net Income | -$7.10M | -27.3% |
| EBITDA | -$6.71M | -81.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.70M | -86.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.58M | 272.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.91% | -40.3% |
| Return On Invested Capital | -585.53% | 921.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.09M | -27.3% |
| Operating Free Cash Flow | -$11.09M | -27.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.99 | -0.79 | 10.17 | 6.46 | -340.67% |
| Price to Tangible Book Value | -0.99 | -0.79 | 10.17 | -46.81 | 7.41% |
| Enterprise Value to EBITDA | -27.29 | -19.19 | -15.38 | -18.46 | 364.13% |
| Return on Equity | -190.7% | -244.2% | -287.9% | -418.1% | -82.18% |
| Total Debt | $0.20M | $0.16M | $0.56M | $0.58M | -97.65% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
